Abstract
Graft versus host disease (GVHD) remains a major life threatening complication and one of the primary barriers to successful allogeneic hematopoietic stem cell transplantation, limiting its application in nonmalignant conditions. Immunosuppression is used for prevention and treatment of GVHD, dampening the graft versus leukemia effect. Intestinal bacteria play a major role in inflammation and augmenting the GVHD cytokine response. Early studies in murine models showed that manipulating the presence of intestinal flora or counteracting its byproducts could limit GVHD. Thus multiple clinical trials targeting gut decontamination were conducted, with the aims of modulating inflammation and protecting against GVHD, with mixed results. More recent work has improved our understanding of the role of intestinal microbiota in the maintenance of innate immunity, mucosal integrity and limiting inflammation. This review offers a summary of this data, with a discussion of potential therapeutic interventions manipulating the intestinal microbiota.
Keywords: Allogeneic hematopoietic stem cell transplantation, graft versus host disease, gut micriobiota, Lactobacillus, Rifaximin.
Mini-Reviews in Medicinal Chemistry
Title:The Role of Intestinal Microbiota in Graft versus Host Disease
Volume: 16 Issue: 3
Author(s): Muna Qayed and John T. Horan
Affiliation:
Keywords: Allogeneic hematopoietic stem cell transplantation, graft versus host disease, gut micriobiota, Lactobacillus, Rifaximin.
Abstract: Graft versus host disease (GVHD) remains a major life threatening complication and one of the primary barriers to successful allogeneic hematopoietic stem cell transplantation, limiting its application in nonmalignant conditions. Immunosuppression is used for prevention and treatment of GVHD, dampening the graft versus leukemia effect. Intestinal bacteria play a major role in inflammation and augmenting the GVHD cytokine response. Early studies in murine models showed that manipulating the presence of intestinal flora or counteracting its byproducts could limit GVHD. Thus multiple clinical trials targeting gut decontamination were conducted, with the aims of modulating inflammation and protecting against GVHD, with mixed results. More recent work has improved our understanding of the role of intestinal microbiota in the maintenance of innate immunity, mucosal integrity and limiting inflammation. This review offers a summary of this data, with a discussion of potential therapeutic interventions manipulating the intestinal microbiota.
Export Options
About this article
Cite this article as:
Qayed Muna and Horan T. John, The Role of Intestinal Microbiota in Graft versus Host Disease, Mini-Reviews in Medicinal Chemistry 2016; 16 (3) . https://dx.doi.org/10.2174/1389557515666150722110547
DOI https://dx.doi.org/10.2174/1389557515666150722110547 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Recent Patents on Thiazole Derivatives Endowed with Antitumor Activity
Recent Patents on Anti-Cancer Drug Discovery An Overview of Data Mining Algorithms in Drug Induced Toxicity Prediction
Mini-Reviews in Medicinal Chemistry The Role of microRNAs in the Pathogenesis and Treatment of Hematopoietic Malignancies
Current Pharmaceutical Design The Calcium-Sensing Receptor as a Regulator of Cellular Fate in Normal and Pathological Conditions
Current Molecular Medicine Autologus Stem Cell Transplatation as a Care Option in Elderly Patients. A Review
Anti-Cancer Agents in Medicinal Chemistry Radiation Therapy in the Early 21st Century: Technological Advances
Current Cancer Therapy Reviews Potential Novel Targets in Breast Cancer
Current Pharmaceutical Biotechnology When Ubiquitin Meets NF-κB: A Trove for Anti-cancer Drug Development
Current Pharmaceutical Design A Perspective on Clinical Islet Transplantation: Past, Present and Developments for Future
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Stimulation of Peroxisome Proliferator-Activated Receptor-Gamma (PPARγ) using Pioglitazone Decreases the Survival of Acute Promyelocytic Leukemia Cells through Up-Regulation of PTEN Expression
Anti-Cancer Agents in Medicinal Chemistry CDC25 Inhibitors as Anticancer Agents Are Moving Forward
Anti-Cancer Agents in Medicinal Chemistry Sjogrens Syndrome and Lymphoma Development
Current Immunology Reviews (Discontinued) Natural Products as Exquisitely Potent Cytotoxic Payloads for Antibody- Drug Conjugates
Current Topics in Medicinal Chemistry NF-κB Signaling Pathway Inhibitors as Anticancer Drug Candidates
Anti-Cancer Agents in Medicinal Chemistry Emerging Indications for Statins: A Pluripotent Family of Agents with Several Potential Applications
Current Pharmaceutical Design Anaplastic Lymphoma Kinase as a Therapeutic Target in Anaplastic Large Cell Lymphoma, Non-Small Cell Lung Cancer and Neuroblastoma
Anti-Cancer Agents in Medicinal Chemistry The Role of Soluble 5'-Nucleotidases in the Conversion of Nucleotide Analogs: Metabolic and Therapeutic Aspects
Current Medicinal Chemistry Clostridium difficile Infection: Associations with Chemotherapy, Radiation Therapy, and Targeting Therapy Treatments
Current Medicinal Chemistry Antiviral Treatment of Cytomegalovirus Infection
Infectious Disorders - Drug Targets Oncomirs: From Tumor Biology to Molecularly Targeted Anticancer Strategies
Mini-Reviews in Medicinal Chemistry